Sonidegib
Hedgehog Inhibitor
DB09143
Approved Indication
Sonidegib is approved for use in the US and EU for treatment of adults with locally advanced basal cell carcinoma (BCC) that has recurred post surgery or radiation therapy. It is also approved for adult patients with BCC who are not eligible for surgery or radiation therapy. (2)
1
Targets
0
Resistance Mutations
2
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
The hedgehog pathway is involved in many human cancers. Sonidegib effectively inhibits the regulator called smoothened (Smo), preventing the hedgehog pathway from functioning. As a result, tumours that depend on the hedgehog pathway are unable to grow. (1)
Details
DrugBank ID
DB09143 ↗
Approval Date
2015-07-24
Molecular Weight
485.507 g/mol
Drug Class
Hedgehog Inhibitor
ATC Codes
L01XX48
Synonyms
Erismodegib
PubChem
CID: 24775005 ↗
ChEMBL
CHEMBL2105737 ↗
SMILES
[H][C@]1(C)CN(C[C@@]([H])(C)O1)C1=CC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=N1
ADMET Profile
Computing properties…
Drug References (DrugBank)